tiprankstipranks
Trending News
More News >
Pressure Biosciences Inc (PBIO)
:PBIO
US Market

Pressure Biosciences (PBIO) Price & Analysis

Compare
61 Followers

PBIO Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

0.76%0.01%99.23%
Mutual Funds
0.01% Other Institutional Investors
99.23% Public Companies and
Individual Investors

PBIO FAQ

What was Pressure Biosciences Inc’s price range in the past 12 months?
Pressure Biosciences Inc lowest stock price was <$0.01 and its highest was $0.21 in the past 12 months.
    What is Pressure Biosciences Inc’s market cap?
    Pressure Biosciences Inc’s market cap is $172.06K.
      When is Pressure Biosciences Inc’s upcoming earnings report date?
      Pressure Biosciences Inc’s upcoming earnings report date is May 15, 2025 which is 21 days ago.
        How were Pressure Biosciences Inc’s earnings last quarter?
        Currently, no data Available
        Is Pressure Biosciences Inc overvalued?
        According to Wall Street analysts Pressure Biosciences Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Pressure Biosciences Inc pay dividends?
          Pressure Biosciences Inc does not currently pay dividends.
          What is Pressure Biosciences Inc’s EPS estimate?
          Pressure Biosciences Inc’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Pressure Biosciences Inc have?
          Pressure Biosciences Inc has 40,967,083 shares outstanding.
            What happened to Pressure Biosciences Inc’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Pressure Biosciences Inc?
            Currently, no hedge funds are holding shares in PBIO

            Company Description

            Pressure Biosciences Inc

            Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was incorporated in 1978 and is based in South Easton, Massachusetts. As of August 2, 2022, Pressure BioSciences, Inc. operates as a subsidiary of Emergent Health Corp.
            Similar Stocks
            Company
            Price & Change
            Follow
            Sintx Technologies
            BioSig Technologies
            INVO Fertility
            Vivos Therapeutics
            Bluejay Diagnostics
            Popular Stocks
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis